Novel important preliminary evidences came from Shi and colleagues investigations, who constructed a DNA methylation-based risk score (RS) to better predict survival in EGFR mutated NSCLC patients after TKIs treatment. This evidence concerns the gene EGFR and non-small cell lung carcinoma.